PARIS–(BUSINESS WIRE)–Regulatory News: STENTYS (Paris:STNT) (FR0010949404 — STNT), a French group specialized in medical technologies for interventional cardiology, today reports activities from MYLIVE 2018, one of the leading Asian congresses in interventional cardiology, held from July 26 to 28, 2018 in Petaling Jaya, Malaysia. The Xposition S sirolimus eluting self-apposing stent was […]
Other News
Janssen Receives Positive CHMP Opinion to Expand INVOKANA® and VOKANAMET® Labelling to Include Positive Data on Cardiovascular Morbidity and Mortality
BEERSE, Belgium–(BUSINESS WIRE)–The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP), of the European Medicines Agency (EMA), has issued a positive opinion to update the INVOKANA® (canagliflozin) and VOKANAMET® (canagliflozin and metformin) labelling including changes to the indication statement for the […]
iRhythm Technologies Announces Second Quarter Financial Results
SAN FRANCISCO, Aug. 01, 2018 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today reported financial results for the three months ending June 30, 2018. Second Quarter 2018 Highlights Second quarter revenue was $35.5M, up 49% compared […]
Caladrius Biosciences to Host Second Quarter 2018 Financial Results Conference Call on Thursday, August 9, 2018 at 4:30 p.m. ET
BASKING RIDGE, N.J., Aug. 02, 2018 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq:CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company with multiple technology platforms targeting select cardiovascular indications and autoimmune diseases, announces that the Company will release financial results for the three and six months ended June 30, 2018 after […]
MyoKardia to Report Second Quarter 2018 Financial Results on Wednesday, August 8, 2018
SOUTH SAN FRANCISCO, Calif., Aug. 01, 2018 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that it will report second quarter 2018 financial and operating results on Wednesday, August 8, 2018. Management will […]
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter 2018 Financial Results
ANN ARBOR, Mich., Aug. 02, 2018 (GLOBE NEWSWIRE) — Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C), today provided bempedoic acid franchise development program updates and financial results for […]
GB Sciences Co-Authors a Peer Reviewed Article Published in the Journal of the American Heart Association Titled: “Cannabinoids, The Heart of the Matter”
LAS VEGAS, Aug. 2, 2018 /PRNewswire/ — GB Sciences, Inc. (OTCQB: GBLX) is pleased to announce the publication of a review article co-authored by GB Sciences and key collaborators in the Journal of the American Heart Association, which explains the potential medical benefits of using cannabinoid-based therapies for the treatment of heart diseases. […]
VisCardia Announces First Implant of the VisONE® System for Treating Heart Failure
PORTLAND, Ore.–(BUSINESS WIRE)–VisCardia Inc., a privately held medical device developer, announced today the first implant of the VisONE® implantable system for heart failure, and the commencement of its VisONE Heart Failure pilot study in Ukraine. The VisONE implantable system delivers VisCardia’s proprietary Asymptomatic Diaphragmatic Stimulation (ADS) therapy to improve cardiac […]
BioAxone BioSciences CEO Lisa McKerracher Speaker at NeuroTrauma2018 Conference
CAMBRIDGE, Mass.–(BUSINESS WIRE)–BioAxone BioSciences, Inc., a biotechnology company focused on developing innovative drugs to treat neurotrauma and neurovascular disorders today announced that CEO Lisa McKerracher, PhD, will be a platform speaker on the Scientific Program, “Update on Clinical Trials in SCI” at NeuroTrauma2018, The 3rd Joint Symposium of the International and National […]
Arrowhead Pharmaceuticals Earns $10 Million Milestone Payment from Amgen
PASADENA, Calif.–(BUSINESS WIRE)–Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has earned a $10 million milestone payment from Amgen following the administration of the first dose of AMG 890, formerly referred to as ARO-LPA, in a clinical study. Amgen is evaluating AMG 890 in a Phase 1 clinical study […]



